What is MyDx?
MyDx operates as a sophisticated science and technology enterprise, bridging the gap between complex chemical analysis and consumer-facing data solutions. The company's core value proposition centers on its handheld chemical analyzer, a device engineered to detect contaminants across diverse mediums including food, water, air, and cannabis. Beyond hardware, the firm has expanded its footprint into the software-as-a-service (SaaS) domain with platforms like MyDx One App and MyDx360. These digital tools serve a broad ecosystem of stakeholders, ranging from individual patients and prescribers to large-scale cultivators, effectively creating a crowdsourced data network that enhances industry-wide safety standards and product efficacy.
How much funding has MyDx raised?
MyDx has raised a total of $7.9M across 2 funding rounds:
Private Equity
$6.9M
Private Equity
$1M
Private Equity (2014): $6.9M, investors not publicly disclosed
Private Equity (2016): $1M led by Kodiak Capital Group, LLC
Key Investors in MyDx
Kodiak Capital Group, LLC
Kodiak is an institutional investor based in Newport Beach, CA, that provides strategic capital to both public and private entities. They specialize in diverse sectors including life sciences, consumer products, and alternative energy, offering flexible equity and debt instruments.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MyDx?
With this major enterprise-level funding, MyDx is poised to scale its operational capacity and deepen its market penetration. The strategic roadmap likely involves enhancing the analytical precision of its hardware while simultaneously expanding the data-processing capabilities of its SaaS offerings. By focusing on the integration of crowdsourced insights, the company aims to solidify its position as a critical infrastructure provider in the cannabis and consumer safety markets. Future growth will likely be driven by strategic partnerships and the continued refinement of its biopharmaceutical research applications, ensuring that the firm remains a leader in the trust-and-verify technology movement.
See full MyDx company page
